Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc. (ATOS) Q3 2024 Earnings

ATOS·Reported November 12, 2024·Before market open

Diluted EPS came in at $-0.05, beat the $-0.06 consensus by $0.01.

Diluted EPS
$-0.05beat by $0.01
Consensus: $-0.06
SEC

SEC Filings

Earnings release8-K not filed yet

Financial Snapshot

Trailing eight quarters through Q3 2024

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q3 2024 Earnings FAQ

Common questions about Atossa Therapeutics, Inc.'s Q3 2024 earnings report.

Atossa Therapeutics, Inc. (ATOS) reported Q3 2024 earnings on November 12, 2024 before market open.

Atossa Therapeutics, Inc. reported diluted EPS of $-0.05 for Q3 2024.

EPS beat the consensus estimate of $-0.06 by $0.01.

You can read the 10-Q periodic report (0000950170-24-124668) directly on SEC EDGAR. The filing index links above go to sec.gov.